GLUE
Monte Rosa Therapeutics Inc

1,226
Mkt Cap
$920.77M
Volume
480,951.00
52W High
$14.62
52W Low
$3.50
PE Ratio
46.30
GLUE Fundamentals
Price
$13.52
Prev Close
$14.14
Open
$14.30
50D MA
$9.91
Beta
1.53
Avg. Volume
1.2M
EPS (Annual)
-$0.9836
P/B
3.55
Rev/Employee
$564,343.28
Loading...
Loading...
News
all
press releases
Integrated Quantitative Investments LLC Acquires New Holdings in Monte Rosa Therapeutics, Inc. $GLUE
Integrated Quantitative Investments LLC bought a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the second quarter, according to its most recent filing with the...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
22,500 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Bailard Inc.
Bailard Inc. bought a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange...
MarketBeat·4d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - Here's Why
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - What's Next...
MarketBeat·7d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Here's Why
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Should You Sell...
MarketBeat·8d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 10.8% Following Analyst Upgrade
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 10.8% on Analyst Upgrade...
MarketBeat·9d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Raised to $13.00
Wells Fargo & Company raised their price objective on Monte Rosa Therapeutics from $10.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday...
MarketBeat·12d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High After Strong Earnings
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 52-Week High on Earnings Beat...
MarketBeat·13d ago
News Placeholder
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +15.38% and +64.26%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +150.00% and +0.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
Zacks·2mo ago

Latest GLUE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.